Your browser doesn't support javascript.
loading
Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads.
Kumar, Amit; Kinneer, Krista; Masterson, Luke; Ezeadi, Ebele; Howard, Philip; Wu, Herren; Gao, Changshou; Dimasi, Nazzareno.
  • Kumar A; Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD 20878, United States.
  • Kinneer K; Oncology Research, MedImmune, Gaithersburg, MD 20878, United States.
  • Masterson L; Spirogen Ltd., QMB Innovation Centre, London, United Kingdom.
  • Ezeadi E; Spirogen Ltd., QMB Innovation Centre, London, United Kingdom.
  • Howard P; Spirogen Ltd., QMB Innovation Centre, London, United Kingdom.
  • Wu H; Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD 20878, United States.
  • Gao C; Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD 20878, United States. Electronic address: gaoc@medimmune.com.
  • Dimasi N; Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD 20878, United States. Electronic address: dimasin@medimmune.com.
Bioorg Med Chem Lett ; 28(23-24): 3617-3621, 2018 12 15.
Article en En | MEDLINE | ID: mdl-30389292
ABSTRACT
Codelivery of multiple therapeutic agents with different anticancer mechanisms can overcome drug resistance as well as generate additive or synergistic anticancer effects that may enhance the antitumor efficacy. Antibody-drug conjugates (ADCs) can be used for highly specific delivery of multiple therapeutic agents with different anticancer mechanisms, though more research is required towards designing flexible platforms on which dual drug ADCs could be prepared. Herein, we describe the synthesis of a heterotrifunctional linker that could be used to construct flexible platforms for preparing dual-cytotoxic drug conjugates in a site-specific manner. As a proof of concept, we synthesized dual drug ADCs carrying monomethyl auristain E (MMAE, tubulin polymerization inhibitor) and pyrrolobenzodiazepine dimer (PBD, DNA minor groove alkylator). We then evaluated the dual drug ADCs for in vitro efficacy and confirmed the dual mechanism of action.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoconjugados / Moduladores de Tubulina Límite: Humans Idioma: En Año: 2018 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoconjugados / Moduladores de Tubulina Límite: Humans Idioma: En Año: 2018 Tipo del documento: Article